Glomerular Galactose-Deficient IgA1(KM55) Positive May Predict Poorer Prognosis in Coexisting Primary Membranous Nephropathy and IgA Nephropathy Patients

被引:0
|
作者
Cheng, Wenrong [1 ]
Wang, Guoqin [1 ]
Guo, Weiyi [1 ]
Sun, Lijun [1 ]
Xu, Xiaoyi [1 ]
Dong, Hongrui [1 ]
Ye, Suhua [2 ]
Geng, Yanqiu [3 ]
Cheng, Hong [1 ]
机构
[1] Capital Med Univ, Beijing Anzhen Hosp, Dept Med, Renal Div, Beijing 100029, Peoples R China
[2] Chifeng Univ, Affiliated Hosp, Div Nephrol, Neimenggu 024000, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 3, Div Nephrol, Beijing 100039, Peoples R China
基金
中国国家自然科学基金;
关键词
galactose-deficient IgA1; KM55; primary membranous nephropathy; IgA nephropathy; IgA deposition; prognosis; DISEASES;
D O I
10.3390/cells12010116
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Primary membrane nephropathy (PMN) and IgA nephropathy (IgAN) are the most common glomerular diseases in China. Because of different pathogenesis, prognosis is significantly different. When the two diseases coexist (PMN/IgAN), the clinicopathological manifestations and prognosis remain unclear. In the present study, we analyzed the clinicopathological characteristics of PMN/IgAN patients, with only IgA deposition (PMN/IgA deposition) patients as controls. Galactose-deficient IgA1(KM55) and M-type Phospholipase A2 Receptor(PLA2R), both in circulation and renal tissues, were detected. Furthermore, prognosis of PMN/IgAN was explored. We found that PMN/IgAN also had some clinical features of IgAN in addition to PMN, such as higher serum albumin, along with a similar heavy proteinuria and lower titers of serum anti-PLA2R antibody. The positive rate of glomerular KM55 in PMN/IgAN was 23.5% (20/85), and 0% (0/29) in PMN/IgA deposition. Among those glomerular KM55 positive patients, KM55 and IgA colocalized mainly along the glomerular mesangial and capillary areas. Unfortunately, there was no significant difference in serum level of Gd-IgA1 between KM55+ and KM55- subgroups in PMN/IgAN patients, similar to the PMN/IgA deposition group. Notably, glomerular KM55 positive may predict a poorer prognosis in PMN/IgAN patients. In conclusion, our study suggested that, when glomerular KM55 staining was positive, this special coexisting PMN/IgAN disorder was prone to have more characteristics of IgAN besides PMN, and may predict poorer prognosis, while the mechanism requires further investigation.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
    Suzuki, Hitoshi
    Allegri, Landino
    Suzuki, Yusuke
    Hall, Stacy
    Moldoveanu, Zina
    Wyatt, Robert J.
    Novak, Jan
    Julian, Bruce A.
    DISEASE MARKERS, 2016, 2016
  • [22] GALACTOSE-DEFICIENT IGA1 REPRESENT A CANDIDATE URINARY MARKER OF IGA NEPHROPATHY
    Suzuki, Hitoshi
    Kano, Toshiki
    Fukao, Yusuke
    Makita, Yuko
    Nihei, Yoshihito
    Kim, Jin Sug
    Lee, Sangho
    Suzuki, Yusuke
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 121 - 121
  • [23] IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1
    Suzuki, Hitoshi
    Moldoveanu, Zina
    Hall, Stacy
    Brown, Rhubell
    Julian, Bruce A.
    Wyatt, Robert J.
    Tomana, Milan
    Tomino, Yasuhiko
    Novak, Jan
    Mestecky, Jiri
    IGA NEPHROPATHY TODAY, 2007, 157 : 129 - 133
  • [24] Intensity of Glomerular Galactose-Deficient IgA1 Deposition Can Be a Marker of Disease Activity in IgA Nephropathy
    Nakayama, Maiko
    Suzuki, Hitoshi
    Fukao, Yusuke
    Lee, Mingfeng
    Kano, Toshiki
    Makita, Yuko
    Suzuki, Yusuke
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 497 - 497
  • [25] Autoantibodies Targeting Galactose-Deficient IgA1 Associate with Progression of IgA Nephropathy
    Berthoux, Francois
    Suzuki, Hitoshi
    Thibaudin, Lise
    Yanagawa, Hiroyuki
    Maillard, Nicolas
    Mariat, Christophe
    Tomino, Yasuhiko
    Julian, Bruce A.
    Novak, Jan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (09): : 1579 - 1587
  • [26] Oxidative Stress and Galactose-Deficient IgA1 as Markers of Progression in IgA Nephropathy
    Camilla, Roberta
    Suzuki, Hitoshi
    Dapra, Valentina
    Loiacono, Elisa
    Peruzzi, Licia
    Amore, Alessandro
    Ghiggeri, Gian Marco
    Mazzucco, Gianna
    Scolari, Francesco
    Gharavi, Ali G.
    Appel, Gerald B.
    Troyanov, Stephan
    Novak, Jan
    Julian, Bruce A.
    Coppo, Rosanna
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (08): : 1903 - 1911
  • [27] The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression
    Zhao, Na
    Hou, Ping
    Lv, Jicheng
    Moldoveanu, Zina
    Li, Yifu
    Kiryluk, Krzysztof
    Gharavi, Ali G.
    Novak, Jan
    Zhang, Hong
    KIDNEY INTERNATIONAL, 2012, 82 (07) : 790 - 796
  • [28] Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
    Kim, Min Jeong
    Schaub, Stefan
    Molyneux, Karen
    Koller, Michael T.
    Stampf, Susanne
    Barratt, Jonathan
    PLOS ONE, 2016, 11 (12):
  • [29] Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients
    Reily, Colin
    Rizk, Dana, V
    Julian, Bruce A.
    Novak, Jan
    BIOTECHNIQUES, 2018, 65 (02) : 71 - 77
  • [30] Correlation of Serum Galactose-Deficient IgA1 and Oxford Class in Cases of IgA Nephropathy
    Shukla, Monika
    Malhotra, Kiran Preet
    Chandra, Abhilash
    Rao, Namrata Sarvepalli
    Ahmad, Mohammad Kaleem
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (11) : 1244 - 1250